Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews
Authors:
Open Access
- 23 August 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 25 (3) , 472-478
Abstract
A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn’s disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.Keywords
Funding Information
- National Institute for Health Research
- Oxford Biomedical Research Centre
This publication has 64 references indexed in Scilit:
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- High frequency of early colorectal cancer in inflammatory bowel diseaseGut, 2008
- A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on AzathioprineGastroenterology, 2005
- Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind, placebo-controlled trialsClinical Gastroenterology and Hepatology, 2004
- Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following yearAlimentary Pharmacology & Therapeutics, 2004
- Slow-Release 5-Amino-Salicylic Acid (Pentasa®) for the Treatment of Active Crohn’s DiseaseDigestion, 1990
- 5-Aminosalicylic Acid in the Treatment of Crohn's Disease: A 16-Week Double-Blind, Placebo-Controlled, Multicentre Study with Pentasa®Scandinavian Journal of Gastroenterology, 1987
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977